Beckman has completed the acquisition of Olympus’ lab-based diagnostics business.
Scott Garrett, chairman, president and chief executive officer of Beckman, said: The completion of this transaction adds considerable product depth and significantly expands our geographic reach and scale. We are confident that the combination of Olympus diagnostics with our business will provide many cross-selling opportunities—the most compelling being promotion of Beckman Coulter’s leading Immunoassay products to the loyal base of Olympus’ chemistry customers.
We remain focused on creating shareholder value through growth, quality and operating excellence. This acquisition demonstrates Beckman Coulter’s commitment to further extend our leadership position in chemistry and sustain our above-market growth in immunoassay, he added.
The acquisition, first announced in February, enhances Beckman Coulter’s position in the field of chemistry and automation.